Trials / Completed
CompletedNCT04657016
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 579 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| OTHER | Placebo | Administered SC |
Timeline
- Start date
- 2021-03-29
- Primary completion
- 2023-04-20
- Completion
- 2023-05-12
- First posted
- 2020-12-07
- Last updated
- 2024-05-16
- Results posted
- 2024-05-16
Locations
65 sites across 4 countries: United States, Argentina, Brazil, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04657016. Inclusion in this directory is not an endorsement.